Company intelligence / Profile preview
AeroRx Therapeutics
- Ownership
- Private
- Development stage
- Other
Overview
AeroRx Therapeutics is developing a proprietary nebulized combination of long acting beta agonist (LABA) and long acting muscarinic antagonist (LAMA) bronchodilators for COPD. The lead product is being developed in partnership with HCmed Innovations using their AdheResp breath-actuated mesh nebulizer. A PK/PD study was planned for 2023 to support a 505(b)(2) NDA submission. The program targets underserved high-risk older COPD patients who cannot optimally use dry powder inhalers due to low inspiratory flow rates. As of March 2025, the highest development phase reported is Phase I/II clinical trials.
- Therapeutic areas
- Pulmonology
- Modalities
- Small moleculesCombination therapeutics for inhalation delivery
- Industry
- Biotech
Drug pipeline
5 assets4 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on AeroRx Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AeroRx Therapeutics.